TFFP — TFF Pharmaceuticals Income Statement
0.000.00%
- $5.14m
- $1.93m
- $0.73m
Annual income statement for TFF Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.088 | 0.496 | 0.734 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 12 | 18.7 | 31.9 | 32.3 | 22.6 |
Operating Profit | -12 | -18.7 | -31.8 | -31.8 | -21.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.9 | -18.6 | -31 | -31.8 | -21.2 |
Net Income After Taxes | -11.9 | -18.6 | -31 | -31.8 | -21.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.9 | -18.6 | -31 | -31.8 | -21.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.7 | -18.6 | -31 | -31.8 | -21.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -49.7 | -22.7 | -31.3 | -26.5 | -11.9 |
Dividends per Share |